Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accounts Payables: 2015-2025

Historic Accounts Payables for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $7.5 million.

  • Spyre Therapeutics' Accounts Payables rose 44.38% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 44.38%. This contributed to the annual value of $666,000 for FY2024, which is 95.98% down from last year.
  • Spyre Therapeutics' Accounts Payables amounted to $7.5 million in Q3 2025, which was up 100.89% from $3.7 million recorded in Q2 2025.
  • Spyre Therapeutics' Accounts Payables' 5-year high stood at $20.8 million during Q2 2023, with a 5-year trough of $666,000 in Q4 2024.
  • For the 3-year period, Spyre Therapeutics' Accounts Payables averaged around $9.0 million, with its median value being $5.2 million (2024).
  • As far as peak fluctuations go, Spyre Therapeutics' Accounts Payables skyrocketed by 2,349.63% in 2023, and later plummeted by 95.98% in 2024.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Accounts Payables stood at $3.3 million in 2021, then crashed by 79.60% to $677,000 in 2022, then spiked by 2,349.63% to $16.6 million in 2023, then plummeted by 95.98% to $666,000 in 2024, then surged by 44.38% to $7.5 million in 2025.
  • Its Accounts Payables stands at $7.5 million for Q3 2025, versus $3.7 million for Q2 2025 and $3.7 million for Q1 2025.